Chemistry for peptide and protein PEGylation

Advanced Drug Delivery Reviews

Volumn 54, Issue 4, 2002, Pages 459-476

  Roberts, M J ^a   Bentley, M D ^a   Harris, J M ^a  

^a Shearwater Corporation   (United States)

Author keywords

PEG chemistry; PEG conjugation; PEG protein; PEGylation

Indexed keywords

ANTIGENS; BIODEGRADATION; MACROMOLECULES; POLYETHYLENE GLYCOLS; POLYPEPTIDES; PROTEINS;

RENAL FILTERATIONS;

BIOTECHNOLOGY;

2,4 BIS(METHOXYPOLYETHYLENE GLYCOL) 6 CHLORO S TRIAZINE; EPITOPE; MACROGOL DERIVATIVE; PEG 'INTRON'; PEG NEUPOGEN; PEG VISOMANT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POLYETHYLENE GLYCOL 4 NITROPHENYLCARBONATE; POLYETHYLENE GLYCOL ACETALDEHYDE; POLYETHYLENE GLYCOL AMINE; POLYETHYLENE GLYCOL BENZOTRIAZOLE CARBONATE; POLYETHYLENE GLYCOL CARBONYLIMIDAZOLE; POLYETHYLENE GLYCOL CARBOXYLIC ACID; POLYETHYLENE GLYCOL DICHLOROTRIAZINE; POLYETHYLENE GLYCOL GRANULOCYTE COLONY STIMULATING FACTOR; POLYETHYLENE GLYCOL HYDRAZIDE; POLYETHYLENE GLYCOL IODOACETAMIDE; POLYETHYLENE GLYCOL MALEIMIDE; POLYETHYLENE GLYCOL ORTHOPYRIDYLDISULFIDE; POLYETHYLENE GLYCOL PROPIONALDEHYDE; POLYETHYLENE GLYCOL SUCCINIMIDYLCARBONATE; POLYETHYLENE GLYCOL SUCCINIMIDYLSUCCINATE; POLYETHYLENE GLYCOL TRESYLATE; POLYETHYLENE GLYCOL TRICHLOROPHENYLCARBONATE; POLYETHYLENE GLYCOL VINYLSULFONE; POLYMER; POLYPEPTIDE; PROTEINASE; UNCLASSIFIED DRUG;

ANTIGENICITY; COVALENT BOND; DRUG BINDING SITE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME DEGRADATION; GLOMERULUS FILTRATION; HEPATITIS C; HUMAN; IMMUNOGENICITY; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PEGYLATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; STRUCTURE ANALYSIS;

DRUG CARRIERS; MODELS, CHEMICAL; PEPTIDES; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 0037124506     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00022-4     Document Type: Article

References (69)

1. Biopharmaceutical benchmarks
2. Removal of amphipathic epitopes from genetically engineered antibodies: Production of modified immunoglobulins with reduced immunogenicity
3. Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein
4. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin
5. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres
6. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
7. Synthesis of polyethylene glycol derivatives
8. Chemistry of polyethylene glycol conjugates with biologically active molecules
9. Peptide and protein PEGylation: A review of problems and solutions
10. Review: Poly(ethylene glycol)s with reactive endgroups. II. Practical consideration for the preparation of protein-PEG conjugates
11. Selective synthesis of heterobifunctional poly(ethylene glycol) derivatives containing both mercapto and acetal terminals
12. A theory for the displacement of proteins and viruses with polyethylene glycol
13. Protein adsorption to and elution from polyether surfaces
14. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
15. Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives
16. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins
17. Polyethylene glycol reactive antibodies in man: Titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors
18. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM
19. Long-acting growth hormones produced by conjugation with polyethylene glycol
20. Use of functionalized poly(ethylene glycol)s for modification of polypeptides
21. Modification of E. Coli asparaginase with 2,4-bis(o-methoxypolyethylene glycol)-6-chloro-s-triazine (activated PEG2); disappearance of binding ability towards anti-serum and retention of enzymatic activity
22. PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimization of coupling techniques
23. Modification and immobilization of proteins with polyethylene glycol tresylates and polysaccharide tresylates: Evidence suggesting a revision of the coupling mechanism and the structure of the polymer-polymer linkage
24. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins
25. A simplified method for the preparation of succinimidyl carbonate polyethylene glycol for coupling to proteins
26. Activation of monomethoxy poly(ethylene glycol) by phenylchloroformate and modification of ribonuclease and superoxide dismutase
27. A new procedure for the synthesis of polyethylene glycol-protein adducts, effects on function, receptor recognition and clearance of superoxide dismutase, lactoferrin and α2-macroglobulin
28. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates
29. Instability of succinyl ester linkages in O2′-monosuccinyl cyclic AMP-protein conjugates at neutral pH
30. Characterization and stability of N-terminally PEGylated rhG-CSF
31. PEGylated recombinant human soluble tumor necrosis factor receptor type I (rHu-sTNF-RI): A novel high-affinity TNF receptor designed for chronic inflammatory diseases
32. Preparation of polyethylene glycol derivatives with two different functional groups at the termini
33. Facile synthesis of α-hydroxy-ω-carboxymethylpolyethylene oxide
34. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site
35. The synthesis of substituted methoxy-poly(ethylene glycol) derivatives suitable for selective protein modification
36. Preparation and characterization of poly(ethylene glycol) vinyl sulfone
37. Protected thiol-polyethylene glycol: A new activated polymer for reversible protein modification
38. The crystal structure of human interferon beta at 2.2-A resolution
39. Hydrazide derivatives of poly(ethylene glycol) and their bioconjugates
40. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins
41. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C
42. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C
43. PEG-interferon-α2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data
44. A branched methoxy 40 kDa polyethyleneglycol (PEG) moiety optimizes the pharmacokinetics (PK) of PEG-interferon α2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)
45. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy
46. The preparation and properties of novel reversible polymer-protein conjugates
47. A hydrolyzable linkage for PEG-proteins
48. Drug delivery systems employing 1,6-elimination: Releasable poly(ethylene glycol) conjugates of proteins
49. New detachable poly(ethylene glycol) conjugates: Cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine
50. Synthesis of poly(ethylene oxide) with heterobifunctional reactive groups at its terminals by an anionic initiator
51. Heterobifunctional poly(ethylene oxide): Synthesis of alpha-methoxy-omega-amino and alpha-hydroxy-omega-amino PEOs with the same molecular weights
52. Formyl-ended heterobifunctional poly(ethylene oxide): Synthesis of poly(ethylene oxide) with a formyl group at one end and a hydroxyl group at the other end
53. Novel polyethylene glycol derivatives for modification of proteins
54. A branched monomethoxypoly(ethylene glycol) for protein modification
55. Branched and linear poly(ethylene glycol): Influence of the polymer structure on enzymological, pharmacokinetic and immunological properties of protein conjugates